Clinical research study enrolling patients living with Idiopathic Pulmonary Fibrosis (IPF)

The IM027068 (ALOFT-IPF) study is testing an investigational drug called BMS-986278 (the "study drug") as a potential new treatment for IPF in adult patients.

You may qualify to participate in this study if you:

- Are 40 years of age or older
- Have been diagnosed with IPF within the past 7 years
- Have not had lung reduction surgery or lung transplantation within the past 12 months
- Do not have plans to undergo lung reduction surgery or lung transplantation within the next 12 months

Additional eligibility requirements will be checked as part of study screening.

If you qualify and choose to participate, you will:

- Be assigned at random (by chance) to receive either the study drug or placebo*
- Take your assigned study drug or placebo tablets by mouth in the morning and in the evening every day during the study treatment
- NOT be able to start Nintedanib or Pirfenidone if you are not taking the medication
- Continue taking Nintedanib or Pirfenidone if you are taking the medication at stable dose for at least 90 days
- Have a minimum of 13 study visits for health assessments in the first year of study treatment with a visit frequency of every 6 weeks after the first month
- Be treated for more than 1 year if you are enrolled at the beginning. Your study visit frequency will be every 12 weeks until the end of the study.
- NOT be charged for the study drug or placebo, study visits, or tests and procedures needed for the study
- Be free to leave the study at any time

* *The placebo is an inactive drug that looks like the investigational drug but contains no active study drug.*

To learn more about this study, please contact:

813-413-7218

athompson@pasotb.com **or** lsalgado@pasotb.com

Meris Clinical Research